Barclays’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.4M | Sell |
309,100
-691,100
| -69% | -$32.7M | ﹤0.01% | 1388 |
|
|
2025
Q4 | $50.9M | Sell |
1,000,200
-1,398,900
| -58% | -$71.5M | 0.01% | 766 |
|
|
2025
Q3 | $133M | Buy |
2,399,100
+2,149,100
| +860% | +$126M | 0.03% | 399 |
|
|
2025
Q2 | $17.3M | Buy |
250,000
+228,500
| +1,063% | +$15.5M | ﹤0.01% | 1216 |
|
|
2025
Q1 | $1.49M | Sell |
21,500
-522,900
| -96% | -$43.2M | ﹤0.01% | 2859 |
|
|
2024
Q4 | $46.8M | Sell |
544,400
-205,600
| -27% | -$22.2M | 0.01% | 691 |
|
|
2024
Q3 | $89.3M | Buy |
+750,000
| New | +$100M | 0.02% | 477 |
|
|
2021
Q1 | – | Sell |
-34,400
| Closed | -$1.2M | – | 5045 |
|
|
2020
Q4 | $1.2M | Hold |
34,400
| – | – | ﹤0.01% | 2624 |
|
|
2020
Q3 | $1.19M | Sell |
34,400
-2,400
| -7% | -$80K | ﹤0.01% | 2530 |
|
|
2020
Q2 | $1.21M | Sell |
36,800
-10,800
| -23% | -$345K | ﹤0.01% | 2585 |
|
|
2020
Q1 | $1.43M | Sell |
47,600
-38,400
| -45% | -$1.14M | ﹤0.01% | 2592 |
|
|
2019
Q4 | $2.49M | Buy |
86,000
+38,000
| +79% | +$1.05M | ﹤0.01% | 2770 |
|
|
2019
Q3 | $1.24M | Buy |
48,000
+39,600
| +471% | +$1M | ﹤0.01% | 3451 |
|
|
2019
Q2 | $214K | Buy |
8,400
+3,400
| +68% | +$84K | ﹤0.01% | 5049 |
|
|
2019
Q1 | $131K | Sell |
5,000
-5,200
| -51% | -$128K | ﹤0.01% | 5149 |
|
|
2018
Q4 | $235K | Sell |
10,200
-9,000
| -47% | -$200K | ﹤0.01% | 4464 |
|
|
2018
Q3 | $453K | Sell |
19,200
-145,000
| -88% | -$3.54M | ﹤0.01% | 4351 |
|
|
2018
Q2 | $3.79M | Buy |
164,200
+132,000
| +410% | +$3.14M | ﹤0.01% | 1963 |
|
|
2018
Q1 | $793K | Sell |
32,200
-97,000
| -75% | -$2.55M | ﹤0.01% | 3494 |
|
|
2017
Q4 | $3.47M | Buy |
129,200
+114,200
| +761% | +$2.9M | ﹤0.01% | 1943 |
|
|
2017
Q3 | $361K | Sell |
15,000
-16,200
| -52% | -$366K | ﹤0.01% | 3915 |
|
|
2017
Q2 | $669K | Sell |
31,200
-12,000
| -28% | -$242K | ﹤0.01% | 3239 |
|
|
2017
Q1 | $740K | Sell |
43,200
-88,400
| -67% | -$1.54M | ﹤0.01% | 3020 |
|
|
2016
Q4 | $2.36M | Buy |
131,600
+95,000
| +260% | +$1.72M | ﹤0.01% | 1981 |
|
|
2016
Q3 | $761K | Buy |
36,600
+27,200
| +289% | +$674K | ﹤0.01% | 2885 |
|
|
2016
Q2 | $253K | Sell |
9,400
-4,000
| -30% | -$110K | ﹤0.01% | 3752 |
|
|
2016
Q1 | $362K | Buy |
13,400
+10,600
| +379% | +$284K | ﹤0.01% | 3391 |
|
|
2015
Q4 | $81K | Sell |
2,800
-6,600
| -70% | -$183K | ﹤0.01% | 4535 |
|
|
2015
Q3 | $254K | Sell |
9,400
-12,200
| -56% | -$345K | ﹤0.01% | 3961 |
|
|
2015
Q2 | $583K | Sell |
21,600
-5,600
| -21% | -$157K | ﹤0.01% | 3351 |
|
|
2015
Q1 | $721K | Buy |
27,200
+20,000
| +278% | +$461K | ﹤0.01% | 3266 |
|
|
2014
Q4 | $151K | Sell |
7,200
-237,800
| -97% | -$5.31M | ﹤0.01% | 4862 |
|
|
2014
Q3 | $5.76M | Buy |
245,000
+223,800
| +1,056% | +$5.15M | 0.01% | 1647 |
|
|
2014
Q2 | $488K | Sell |
21,200
-3,200
| -13% | -$70.7K | ﹤0.01% | 4008 |
|
|
2014
Q1 | $549K | Sell |
24,400
-26,600
| -52% | -$567K | ﹤0.01% | 3866 |
|
|
2013
Q4 | $938K | Sell |
51,000
-95,000
| -65% | -$1.66M | ﹤0.01% | 3466 |
|
|
2013
Q3 | $2.47M | Buy |
146,000
+56,000
| +62% | +$942K | ﹤0.01% | 2344 |
|
|
2013
Q2 | $1.4M | Buy |
+90,000
| New | +$1.5M | ﹤0.01% | 2957 |
|
Other funds holding NVO
DAM
F
Barclays's NVO Position: Q1 2026 in Review
Barclays increased its Novo Nordisk (NVO) stake by 246% in Q1 2026, buying an estimated $111M and bringing the position to 3,283,636 shares worth $121M. The position accounts for 0.03% of the portfolio, ranked #437.
Barclays first reported a position in NVO in Q2 2013 and has held it in 51 quarters since. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Barclays held 3,283,636 shares of Novo Nordisk worth $121M as of Q1 2026.
- Barclays bought 2,333,364 Novo Nordisk shares in Q1 2026, an estimated $111M.
- Novo Nordisk made up 0.03% of Barclays's portfolio in Q1 2026, its #437 holding.
- Barclays first reported a position in Novo Nordisk in Q2 2013 and has held it in 51 quarters since.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.